Hormones in advanced cancer.
D000152:Acne Vulgaris / Q000139:chemically induced; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000315:Adrenalectomy; D000728:Androgens / Q000009:adverse effects; D000732:Androstanols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006628:Hirsutism / Q000139:chemically induced; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D006973:Hypertension / Q000139:chemically induced; D007016:Hypophysectomy; D008297:Male; D009277:Nandrolone / Q000627:therapeutic use; D009640:Norethindrone / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011374:Progesterone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy; D013963:Thyroid Hormones / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D014565:Urogenital Neoplasms / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy; D014667:Vasopressins / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000728:Androgens; D000732:Androstanols; D004967:Estrogens; D006728:Hormones; D013963:Thyroid Hormones; D014667:Vasopressins; D011374:Progesterone; D009277:Nandrolone; D009640:Norethindrone